{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:52:33Z","timestamp":1781632353292,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1929,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Eisai Ltd","award":["NCT01104155"],"award-info":[{"award-number":["NCT01104155"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1093\/annonc\/mdu174","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T04:11:30Z","timestamp":1400127090000},"page":"1578-1584","source":"Crossref","is-referenced-by-count":11,"title":["Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer"],"prefix":"10.1016","volume":"25","author":[{"given":"T.S.","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.L.","family":"Geater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Iannotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Thongprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Spira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.T.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Reyderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gopalakrishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Garzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdu174_bb0010","unstructured":"J Ferlay HR Shin F Bray. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10. http:\/\/globocan.iarc.fr (11 December 2012, date last accessed)."},{"key":"10.1093\/annonc\/mdu174_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1093\/annonc\/mdu174_bb0020","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0025","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0030","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu174_bb0035","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","article-title":"Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial","volume":"372","author":"Kim","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu174_bb0040","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdu174_bb0045","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.2005.05.1474","article-title":"Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial","volume":"25","author":"Gatzemeier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0050","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1200\/JCO.2005.02.840","article-title":"TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0055","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0060","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1200\/JCO.2004.08.001","article-title":"Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial\u2014INTACT 1","volume":"22","author":"Giaccone","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0065","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1200\/JCO.2008.21.5541","article-title":"Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer","volume":"27","author":"Mok","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0070","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1097\/JTO.0b013e31822ae061","article-title":"Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I\/II trial","volume":"6","author":"Sangha","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/138945010790030983","article-title":"Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer","volume":"11","author":"Li","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1093\/annonc\/mdu174_bb0080","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdu174_bb0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cllc.2011.06.010","article-title":"A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer","volume":"13","author":"Spira","year":"2012","journal-title":"Clin Lung Cancer"},{"key":"10.1093\/annonc\/mdu174_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdu174_bb0095","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jchromb.2008.09.013","article-title":"A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma","volume":"875","author":"Desjardins","year":"2008","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1093\/annonc\/mdu174_bb0100","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdu174_bb0105","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","article-title":"The use of confidence or fiducial limits illustrated in the case of the binomial","volume":"26","author":"Clopper","year":"1934","journal-title":"Biometrika"},{"key":"10.1093\/annonc\/mdu174_bb0110","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1124\/dmd.111.042762","article-title":"Mass balance study of [14C]eribulin in patients with advanced solid tumors","volume":"40","author":"Dubbelman","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"Suppl. 9","key":"10.1093\/annonc\/mdu174_bb0115","article-title":"A randomized phase II study comparing erlotinib (E) versus E alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 study","volume":"23","author":"Aerts","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0120","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1470-2045(13)70254-7","article-title":"Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial","volume":"14","author":"Wu","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdu174_bb0125","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2125.2012.04381.x","article-title":"Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin","volume":"75","author":"Devriese","year":"2013","journal-title":"Br J Clin Pharmacol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419348148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419348148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/25\/8\/1578\/16703335\/mdu174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:40:55Z","timestamp":1624520455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419348148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0923753419348148"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdu174","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}